Beyond the Diagnosis: How Saudi Arabia’s Oncology Market Is Scaling Cancer Care to 2030

Policy is one of the strongest accelerators. Middle East Health notes that, through the Health Sector Transformation Program set out in Vision 2030, the Kingdom has already taken significant steps to prepare for significantly higher levels of cancer and other non-communicable diseases, including improving quality of care and patients’ quality of life. Ken Research adds a more specific mandate: the Health Sector Transformation Program, issued by the Ministry of Health in 2021, requires genomic integration in cancer care through national screening programs and precision oncology pathways. It also requires all public hospitals to adopt genomic testing for high-risk cancers, with compliance thresholds of 80% coverage for eligible patients and standardized licensing for genomic labs.

From Genomics to AI: The New Scaling Tools in Cancer Care

Genomics is moving from specialist use to structured service lines in major cities. Ken Research values the Saudi Arabia genomics in cancer care market at USD 320 million and highlights Riyadh, Jeddah, and Dammam as leading hubs due to advanced healthcare infrastructure and the concentration of medical institutions, research facilities, and universities. In segmentation, diagnostic testing is described as the leading sub-segment, while hospitals are the dominant end-user segment. In practice, this reinforces a scaling pattern: mainstream hospital workflows adopt more testing, then use results to support precision oncology decisions, rather than leaving advanced diagnostics to a narrow set of referral centers.

AI is becoming the companion layer that helps systems handle volume, complexity, and consistency. A ResearchAndMarkets.com offering summarized by GlobeNewswire estimates the Middle East AI in oncology market at USD 111.33 million in 2024, projecting a CAGR of 21.94% from 2025 to 2033. The same report ties growth to cancer prevalence, government initiatives, and digital technology, and it segments AI use across diagnostics (including pathology and cancer radiology), radiation therapy, R&D, chemotherapy, and immunotherapy, with hospitals included as a key end-use. For Saudi Arabia, that matters because scaling is not only about new treatments; it is also about making diagnosis and treatment planning more reliable as demand rises.

At the disease level, access and stage at diagnosis still shape outcomes and spending pressure. Ken Research values the Saudi Arabia stomach (gastric) cancer market at USD 30 million and notes that the advanced stage segment dominates due to late diagnosis, often requiring more aggressive treatment options including chemotherapy and palliative care. The same source flags an access imbalance: specialized oncology services are concentrated in major urban centers, while approximately 62% of the population lives outside those centers. This is where the Saudi oncology market’s next phase is defined: expanding precision pathways, standardizing lab quality via licensing, and pairing hospital-led delivery with digital and virtual models that reduce the distance between patients and specialists.